Microbot net loss widens to $5.63 million in Q2 FY26; revenue rises to $241,000
MBOT•Outlook and risks
- Management reiterated it expects CE Mark approval for LIBERTY in the second half of 2026, while flagging ongoing Israel-region conflict risks.
Quarterly results
- Microbot posted a GAAP net loss of USD 5.63 million in Q2 2026, widening from USD 3.5 million a year earlier.
- Revenue was USD 241,000, compared with no revenue a year earlier, as LIBERTY Endovascular Robotic System sales ramped post-launch.
- Cost of revenues totaled USD 884,000, driven by manufacturing and commercialization costs tied to LIBERTY units for sale.
- Sales, general and administrative expense climbed to USD 3.68 million from USD 1.61 million on higher payroll and commercialization-related spending.
Related News
Shares of Gap Down About 4% After Barclays Downgrades to 'Equal-Weight'
GAP•
Lockheed Martin Corp Makes Multimillion Dollar Investment To Develop Modular Payload Delivery System For Scaled Hypersonic Missions
LMT•
